medigraphic.com

2021, Number 4

<< Back Next >>

Rev Hematol Mex 2021; 22 (4)

Castleman’s disease

Anzures-GómezPK, Camacho-Becerra C, Castro-Rubio JA, Rosas-Tototzintle R, Díaz-Castillo J, Abendaño-Rivera DF, González-González L, García-Juárez MA, Escutia-Cuevas HH, Navarro-Alvarado R

Language: Spanish
References: 33
Page: 225-231
PDF size: 257.13 Kb.


ABSTRACT

Background: Castleman’s disease is a rare heterogeneous lymphoproliferative disorder, with an estimated incidence of approximately 1:100,000 patients; it was first described in 1954 by the pathologist Benjamin Castleman. It is also known as angiofollicular hyperplasia, giant lymph node hyperplasia, benign giant lymphoma, angiomatous lymphoid hamartoma, lymph node hamartoma and follicular lympho-reticuloma. It is classified into two big groups: unicentric Castleman’s disease and multicentric Castleman’s disease and, according to its histopathological pattern, in 1972 Keller classified 3 variants: the hyaline vascular, the plasma cell variant and the mixed variant.
Clinical case: A 36-year-old female patient with multicentric Castleman’s disease in its hyaline vascular variant.
Conclusions: Castleman’s disease is a rare lymphoproliferative process, with an excellent prognosis in the unicentric variety and infrequent relapses; however, there is little information about these patients and a high degree of diagnostic suspicion is required and, since there are no specific clinical and radiographic data, histopathological analysis is essential to establish the diagnosis early and provide timely treatment, which improves the prognosis of these patients.


REFERENCES

  1. Dégot T, Métivier A-C, Casnedi S, Chenard M-P, KesslerR. [Thoracic manifestations of Castleman’s disease]. RevPneumol Clin 2009; 65 (2): 101-7. doi: 10.1016/j.pneumo.2008.12.004.

  2. CASE records of the Massachusetts General Hospital WeeklyClinicopathological Exercises: Case 40011. N Engl J Med1954; 250 (1): 26-30.

  3. Bowne WB, Lewis JJ, Filippa DA, Niesvizky R, Brooks AD,Burt ME, et al. The management of unicentric and multicentricCastleman’s disease: a report of 16 cases anda review of the literature. Cancer 1999; 85 (3): 706-17.doi: 10.1002/(sici)1097-0142(19990201)85:3<706::aidcncr21>3.0.co;2-7.

  4. Wu D, Lim MS, Jaffe ES. Pathology of Castleman disease.Hematol Oncol Clin North Am 2018; 32 (1): 37-52. DOI:10.1016/j.hoc.2017.09.004.

  5. Keller AR, Hoch hol ze r L , C a st l ema n B . H ya l i -ne-vascular and plasma-cell types of giant lymphnode hyperplasia of the mediastinum and other locations.Cancer 1972; 29 (3): 670-83. https://doi.org/10.1002/1097-0142(197203)29:3%3C670::AIDCNCR2820290321%3E3.0.CO;2-%23.

  6. Kligerman SJ, Auerbach A, Franks TJ, Galvin JR. Castlemandisease of the thorax: Clinical, radiologic, and pathologiccorrelation: From the Radiologic Pathology Archives. Radio-Graphics 2016; 36 (5): 1309-32. https://doi.org/10.1148/rg.2016160076.

  7. Casper C. The aetiology and management of Castlemandisease at 50 years: translating pathophysiologyto patient care. Br J Haematol 2005; 129 (1): 3-17. doi:10.1111/j.1365-2141.2004.05311.x.

  8. Simpson D. Epidemiology of Castleman disease. HematolOncol Clin North Am 2018; 32 (1): 1-10. doi: 10.1016/j.hoc.2017.09.001.

  9. Talat N, Belgaumkar AP, Schulte K-M. Surgery in Castleman’disease: a systematic review of 404 publishedcases. Ann Surg 2012; 255 (4): 677-84. doi: 10.1097/SLA.0b013e318249dcdc.

  10. Soumerai JD, Sohani AR, Abramson JS. Diagnosis and managementof Castleman disease. Cancer Control 2014; 21(4): 266-78. doi: 10.1177/107327481402100403.

  11. Akram W, Degliuomini K, Wallack MK, Huang S, OkechukwuE, Tam E. Unicentric Castleman’s disease masquerading asa carcinoid tumor of the small intestine. 2016. https://doi.org/10.1177%2F000313481608200924.

  12. Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, LeeJS, et al. A multidimensional index and staging system foridiopathic pulmonary fibrosis. Ann Intern Med 2012; 156(10): 684-91. doi: 10.7326/0003-4819-156-10-201205150-00004.

  13. Jones NW, Fountain TR, Thakral B, Eldibany M. Castleman’sdisease in the orbit of a 17-year-old girl: a case report.Ophthal Plast Reconstr Surg 2014; 30 (1): e17-20. doi:10.1097/IOP.0b013e31828b0e18.

  14. Tsai MH, Pai HH, Yen PT, Huang TS, Ho YS. NasopharyngealCastleman’s disease. J Formos Med Assoc 1996; 95 (11):877-80.

  15. El-Osta HE, Kurzrock R. Castleman’s disease: from basicmechanisms to molecular therapeutics. Oncologist 2011;

  16. 16 (4): 497-511. doi: 10.1634/theoncologist.2010-0212.16. Chang K-C, Wang Y-C, Hung L-Y, Huang W-T, Tsou J-H, MJones D, et al. Monoclonality and cytogenetic abnormalitiesin hyaline vascular Castleman disease. Mod Pathol 2014; 27(6): 823-31. doi: 10.1038/modpathol.2013.202.

  17. Li Z, Lan X, Li C, Zhang Y, Wang Y, Xue W, et al. RecurrentPDGFRB mutations in unicentric Castleman disease.Leukemia 2019; 33 (4): 1035-8. doi: 10.1038/s41375-018-0323-6.

  18. Bates D, Hillman N, Williams B, Neal C, Pocock T. Regulationof microvascular permeability by vascular endothelialgrowth factors. J Anat 2002; 200 (6): 581-97. https://doi.org/10.1046%2Fj.1469-7580.2002.00066.x.

  19. Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Taeho L, AozasaK, et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman’s disease. Blood 1989; 74 (4): 1360-7.

  20. Chan K-L, Lade S, Prince HM, Harrison SJ. Update and newapproaches in the treatment of Castleman disease. J BloodMed 2016; 7: 145-58. doi: 10.2147/JBM.S60514.

  21. Yoshizaki K, Murayama S, Ito H, Koga T. The role of interleukin-6 in Castleman disease. Hematol Oncol Clin NorthAm 2018; 32 (1): 23-36. doi: 10.1016/j.hoc.2017.09.003.

  22. Sullivan RJ, Pantanowitz L, Casper C, Stebbing J, Dezube BJ.HIV/AIDS: epidemiology, pathophysiology, and treatmentof Kaposi sarcoma-associated herpesvirus disease: Kaposisarcoma, primary effusion lymphoma, and multicentricCastleman disease. Clin Infect Dis 2008; 47 (9): 1209-15.https://doi.org/10.1086%2F592298.

  23. Sevilla-Lizcano DB, Frias-Soria CL, Ortiz-Hidalgo C. Castlemandisease. Histopathological and immunohistochemicalanalysis of 39 cases. Gac Méd Méx 2017; 153: 499-507

  24. McCarty MJ, Vukelja SJ, Banks PM, Weiss RB. Angiofollicularlymph node hyperplasia (Castleman’s disease).Cancer Treat Rev 1995; 21 (4): 291-310. doi: 10.1016/0305-7372(95)90034-9.

  25. van Rhee F, Stone K, Szmania S, Barlogie B, Singh Z. Castlemandisease in the 21st century: an update on diagnosis,assessment, and therapy. Clin Adv Hematol Oncol 2010;8 (7): 486-98.

  26. Wong RSM. Unicentric Castleman disease. HematolOncol Clin North Am 2018; 32 (1): 65-73. doi: 10.1016/j.hoc.2017.09.006.

  27. Chronowski GM, Ha CS, Wilder RB, Cabanillas F, Manning J,Cox JD. Treatment of unicentric and multicentric Castlemandisease and the role of radiotherapy. Cancer 2001; 92 (3):670-6. doi: 10.1002/1097-0142(20010801)92:3<670::aidcncr1369>3.0.co;2-q.

  28. Herrada J, Cabanillas F, Rice L, Manning J, Pugh W. Theclinical behavior of localized and multicentric Castlemandisease. Ann Intern Med 1998; 128 (8): 657-62. doi:10.7326/0003-4819-128-8-199804150-00010.

  29. Maladie de Castleman [Internet]. Haute Autorité deSanté. [citado 11 de noviembre de 2020]. Disponible en:https://www.has-sante.fr/jcms/p_3121172/fr/maladiede-castleman

  30. Dispenzieri A, Fajgenbaum DC. Overview of Castlemandisease. Blood 2020; 135 (16): 1353-64. doi: 10.1182/blood.2019000931.

  31. Mitsos S, Stamatopoulos A, Patrini D, George RS, LawrenceDR, Panagiotopoulos N. The role of surgical resection in UnicentricCastleman’s disease: a systematic review. Adv RespirMed 2018; 86 (1): 36-43. doi: 10.5603/ARM.2018.0008.

  32. Bandera B, Ainsworth C, Shikle J, Rupard E, Roach M. Treatmentof unicentric Castleman disease with neoadjuvant rituximab.Chest 2010; 138 (5): 1239-41. doi: 10.1378/chest.09-2084.

  33. Abid MB, Peck R, Abid MA, Al-Sakkaf W, Zhang Y, DunnillGS, et al. Is tocilizumab a potential therapeutic option forrefractory unicentric Castleman disease? Hematol Oncol2018; 36 (1): 320-3. doi: 10.1002/hon.2420.




2020     |     www.medigraphic.com